Kissei Pharmaceutical Co., Ltd. (KIS.F)

17.60 0.00 (0.00%) As of 08:05AM CEST. Market open.

Kissei Pharmaceutical Co., Ltd.

19-48, Yoshino
Matsumoto 399-8710
Japan
81 2 6325 9081
https://www.kissei.co.jp

Sector(s): 
Industry: 
Full Time Employees: 1,359

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Mutsuo Kanzawa	Chairman & CEO	N/A	N/A	1949
Mr. Yasuo Takehana	President, COO & Director	N/A	N/A	1960
Mr. Takahide Kitahara	GM of Financial Management Department, MD & Director	N/A	N/A	1962
Mr. Yoshio Furihata	Senior Advisor & Director	N/A	N/A	1962
Mr. Keiji Fukushima	Executive VP & Director	N/A	N/A	1956
Mr. Tetsu Takayama	Executive MD & Director	N/A	N/A	1961
Hiroshi Noake	GM of Pharmaceutical Sales Headquarters & Director	N/A	N/A	1964
Keiji Miyazawa	GM of Research Division & Director	N/A	N/A	1967

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Kalogra tablets, for the treatment of ulcerative colitis; Tabuneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Malizeb tablets; Tavaris tablets for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, facility and equipment management, and information gathering and development support services. Further, the company engages in the information equipment rentals; insurance agency business; manufactures and sells noodles; and undertakes construction of factories, research institutes, offices, etc., as well as computer system design and development, and cloud services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is headquartered in Matsumoto, Japan.

Corporate Governance

Kissei Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.